Radioimmunotherapy for NHL: Experience of ⁹⁰Y-Ibritumomab Tiuxetan in Clinical Practice

References

• Edwards, BK., Howe, H.L., Ries, L.A., Thun, M.J., Rosenberg, H.M., Yancik, R., et al. (2002) "Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on US cancer burden", Cancer, 94, 2766–2792.
   PubMed Web of Science ®Google Scholar
• Ries, L.A., Eisner, M.P., Kosary, C.L., Hankey, B.F., Miller, B.A., Clegg, L., et al. (2003) SEER Cancer Statistics Review, 1975-2000, Bethesda, MD: National Cancer Institute.
   Google Scholar
• Nakamura, K., Kunitake, N., Kimura, M., Shioyama, Y., Terashima, H. and Masuda, K. (2000) "Radiotherapy for localized relapse in patients with non-Hodgkin's lymphoma: a preliminary report", Radiat. Med., 18, 245–248.
   Google Scholar
• Marromatis, B.H. and Cheson, B.D. (2001) "New strategies for the treatment of indolent non-Hodgkin's lymphomas", Oncology Spectrums, 2, 706–716.
   Google Scholar
• Fisher, R.I. (2000) "Current therapeutic paradigm for the treatment of non-Hodgkin's lymphoma", Semin. Oncol., 27, 2–8.
   Google Scholar
• Hagenbeek, A. and Kluin, P.M. (1999) Non-Hodgkin's lymphomas. In: Textbook of Malignant Haematology, edited by L. Degos, D.C. Linch and B. Lowenberg. Pp. 635–684. London: Martin Dunitz, London.
   Google Scholar
• Horning, S.J. (1993) "Natural history of and therapy for the indolent non-Hodgkin's lymphomas", Semin. °ma, 20, 75–88.
   Google Scholar
• Press, 0.W., Leonard, J.P., Coiffier, B., Levy, R. and Timmerman, J. (2001) "Immunotherapy of Non-Hodgkin's lymphomas", Hema-tology (Am. Soc. Hematol. Educ. Program), 221— 240.
   Google Scholar
• Vose, J.M. (2000) "Therapeutic uses of MAbs directed against CD20", Cytotherapy, 2, 455 — 461.
   Google Scholar
• Hohenstein, M. (2002) "Immunotherapy: a novel treatment for Non-Hodgkin's lymphoma", Semin. Oncol. Nurs., 18, 10–15.
   PubMedGoogle Scholar
• Juweid, M.E. (2002) "Radioimmunotherapy of B-cell non-Hodg-kin's lymphoma: from clinical trials to clinical practice", J. Nucl. Med., 43, 1507–1529.
   Web of Science ®Google Scholar
• Cheson, B.D. (2003) "Radioimmunotherapy of non-Hodgkin lymphomas", Blood, 101, 391— 398.
   Google Scholar
• Chanan-Khan, A. and Czuczman, M.S. (2002) "Radioimmunother-apy in non-Hodgkin lymphoma", Curr. Opin. Oncol., 14, 484–489.
   PubMed Web of Science ®Google Scholar
• Dillman, R.O. (2002) "Radiolabeled anti-CD20 monoclonal anti-bodies for the treatment of B-cell lymphoma", J. Clin. °flea, 20, 3545 — 3557.
   Google Scholar
• Meredith, R.F. and Knox, S.J. (2001) "Radioimmunotherapy of B-cell NHL", Curr. Pharm. Biotechnol., 2, 327–339.
   Google Scholar
• Postema, E.J., Boerman, 0.C., Oyen, W.J., Raemaekers, J.M. and Corstens, F.H. (2001) "Radioimmunotherapy of B-cell non-Hodgkin's lymphoma", Eur. J. Nucl. Med., 28, 1725–1735.
   PubMedGoogle Scholar
• DeNardo, G.L., O'Donnell, R.T. and DeNardo, S.J. (2001) "Radiolabeled anti-lymphoma antibodies", Cancer Chemother. Biol. Response Modif., 19, 297–308.
   PubMedGoogle Scholar
• Zelenetz, A.D. (1999) "Radioimmunotherapy for lymphoma", Curr. Opin. °flea, 11, 375–380.
   Google Scholar
• Press, 0.W., Appelbaum, F., Ledbetter, J.A., Martin, P.J., Zarling, J., Kidd, P., et al. (1987) "Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas", Blood, 69, 584–591.
   PubMed Web of Science ®Google Scholar
• Kaminski, M.S., Zasadny, K.R., Francis, I.R., Milik, A.W., Ross, C.W., Moon, S.D., et al. (1993) "Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody", N. Engl. J. Med., 329, 459 — 465.
   Google Scholar
• Kaminski, M.S., Zasadny, KR., Francis, I.R., Fenner, M.C., Ross, C.W., Milik, A.W., et al. (1996) "Iodine-131-anti-B1 radioimmu-notherapy for B-cell lymphoma", J. Chit Oncol., 14, 1974–1981.
   Google Scholar
• Kaminski, M.S., Estes, J., Zasadny, KR., Francis, I.R., Ross, C.W., Tuck, M., et al. (2000) "Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience", Blood, 96, 1259–1266.
   Google Scholar
• Vose, J.M., Wahl, R.L., Saleh, M., Rohatiner, A.Z., Knox, Si., Radford, J.A., et al. (2000) "Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas", J. Clin. Oncol., 18, 1316–1323.
   Web of Science ®Google Scholar
• Kaminski, M.S., Zelenetz, A.D., Press, 0.W., Saleh, M., Leonard, J., Fehrenbacher, L., et al. (2001) "Pivotal study of iodine 1131 tositumomab for chemotherapy-refractory low-grade or trans-formed low-grade B-cell non-Hodgkin's lymphomas", J. Clin. °ilea, 19, 3918 — 3928.
   Google Scholar
• Gregory, S., Coleman, M., Ali, A., O'Brien, T.M., Subramanian, A., Kostakoglu, L., et al. (2000) "Efficacy and safety of Bexxar in the expanded access study: Interim report from two institutions", Blood, 96, 2386 (Abstract 4758).
   Google Scholar
• Grillo-Lopez, A.J. (2002) "Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma", Expert Rev. Anticancer Ther., 2, 485 — 493.
   PubMedGoogle Scholar
• Harrington, K.J. and Epenetos, A.A. (1994) "Recent developments in radioimmunotherapy", Clin. °flea (R. Coll. Radiol.), 6, 391 — 398.
   Google Scholar
• Harrison, A., Walker, C.A. and Parker, D. (1991) "The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates", Nuclear Medicine Biology, 18, 469–479.
   Web of Science ®Google Scholar
• Roselli, M., Schlom, J., Gansow, 0.A., Brechbiel, M.W., Mirzadeh, S., Pippin, C.G., et al. (1991) "Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies", Int. J. Rad. Appl. Instrum. B, 18, 389— 394.
   Google Scholar
• Sharkey, R.M., Motta-Hennessy, C., Gansow, 0.A., Brechbiel, M.W., Fand, I., Griffiths, G.L., etal. (1990) "Selection of a DTPA chelate conjugate for monoclonal antibody targeting to a human colonic tumor in nude mice", Int. J. Cancer, 46, 79–85.
   PubMed Web of Science ®Google Scholar
• Kozak, R.W., Raubitschek, A., Mirzadeh, S., Brechbiel, M.W., Junghans, R.P., Gansow, 0.A., et al. (1989) "Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity", Cancer Res., 49, 2639— 2644.
   Google Scholar
• Press, W.O. (2000) "Physics for practitioners: the use of radi-olabeled monoclonal antibodies in B-cell non-Hodgkin's lympho-ma", Semin. Hematol., 37, 2–8.
   Web of Science ®Google Scholar
• Krasner, C. and Joyce, R.M. (2001) "Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma", Curr. Pharm. Biotechnol., 2, 341 — 349.
   Google Scholar
• Wiseman, G.A., White, C.A., Witzig, T.E., Gordon, L.I., Emma-nouilides, C., Raubitschek, A., et al. (1999) "Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody", Clin. Cancer Res., 5, 3281s — 3286s.
   Google Scholar
• Witzig, T.E., White, C.A., Wiseman, G.A., Gordon, L.I., Emma-nouilides, C., Raubitschek, A., et al. (1999) "Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20( +) B-cell non-Hodgkin's lymphoma", J. Clin. Oncol., 17, 3793–3803.
   PubMed Web of Science ®Google Scholar
• Wiseman, G.A., Gordon, L.I., Multani, P.S., Witzig, T.E., Spies, S., Bartlett, N.L., et al. (2002) "Ibritumomab tiuxetan radioimmu-notherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial", Blood, 99, 4336–4342.
   Google Scholar
• Witzig, T.E., Flinn, I.W., Gordon, L.I., Emmanouilides, C., Czuczman, M.S., Saleh, M.N., et al. (2002) "Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with ritux-imab-refractory follicular non-Hodgkin's lymphoma", J. Clin. Oncol., 20, 3262— 3269.
   Web of Science ®Google Scholar
• Witzig, T.E., Gordon, L.I., Cabanillas, F., Czuczman, M.S., Emmanouilides, C., Joyce, R., et al. (2002) "Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunother-apy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodg-kin's lymphoma", J. Clin. Oncol., 20, 2453–2463.
   Web of Science ®Google Scholar
• Schilder, R.J., Witzig, T., Gordon, L., Emmanouilides, CE., Bartlett, N.L., Flinn, I.W., et al. (2002) "90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy does not preclude effective delivery of subsequent therapy for lymphoma", Proc. Am. Soc. Clin. Oncol., 21, 276a (Abstract 1064).
   Google Scholar
• Gordon, L., Witzig, T., Schilder, R., Bartlett, N., Emmanouilides, C., Multani, P., et al. (2001) "High-dose therapy can be safely and successfully administered after Zevalin treatment", Proc. Am. Soc. Clin. °flea, 20, 232b (Abstract 2681).
   Google Scholar
• Ansell, S.M., Ristow, KM., Habermann, TM., Wiseman, G.A. and Witzig, T.E. (2002) "Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma", J. Clin. Oncol., 20, 3885 — 3890.
   Web of Science ®Google Scholar
• Emmanouilides, C., Witzig, T., Molina, A., Gordon, L., Multani, P., Wiseman, G., et al. (2003) "Improved safety and efficacy of Y-90-ibritumomab tiuxetan (Zevalin) radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low grade, follicular and transformed B-cell non-Hodgkin's lymphoma (NHL)", Proc. Am. Soc. Clin. Oncol., 22, 595 (Abstract 2392).
   Google Scholar
• Flinn, I.W., Witzig, T.E., White, CA., Gordon, L., Emmanouilides, C., Cripe, L.D., et al. (2001) "The Zevalin radioimmunotherapy (RIT) regimen is active in heavily pre-treated, bulky, rituximab refractory NHL", Proc. Am. Soc. Clin. Oncol., 20, 286a (Abstract 1141).
   Google Scholar
• Emmanouilides, C., Witzig, T., Gordon, L., Wiseman, G., Bartlett, N., Murray, J., et al. (2001) "Zevalin radioimmunotherapy (RIT) is safe and effective in geriatric patients with low-grade, follicular or CD20 + transformed (LG/F/T) non-Hodgkin's lymphoma (NHL)", Proc. Am. Soc. Clin. Oncol., 20, 286a (Abstract 1143).
   Google Scholar
• Wiseman, G.A., Kornmehl, E., Leigh, B., Erwin, W.D., Podoloff, D.A., Spies, S., et al. (2003) "Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials", J. Nucl. Med., 44, 465–474.
   Web of Science ®Google Scholar
• Wiseman, G.A., Leigh, B.R. and Erwin, W.D. (2001) "Urinary clearance of 90Y activity following Zevalin radioimmunotherapy of B-cell non-Hodgkin's lymphoma", Journal of Nuclear Medicine, 42, 286P.
   Google Scholar
• Witzig, T.E., White, CA., Gordon, L.I., Wiseman, G.A., Emma-nouilides, C., Murray, J.L., et al. (2003) "Safety of Yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma", J. Clin. Oncol., 21, 1263— 1270.
   Google Scholar
• Czuczman, M., Witzig, T.E., Gaston, I., Skikne, B.S., Dimitrov, G., Gordon, L.I., et al. (2002) "Zevalin radioimmunotherapy is not associated with an increased incidence of secondary myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)", Blood, 100, 375a (Abstract 1386).
   Google Scholar
• Wiseman, G.A., Colgan, J.P., Inwards, DJ., Micallef, I.N.M., Gansen, D.N., Porrata, L.F., et al. (2002) "Yttrium-90 Zevalin phase I sequential dose radioimmunotherapy trial of patients with relapsed low grade and follicular B-cell non-Hodgkin's lymphoma (NHL): Preliminary results", Blood, 100, 358a (Abstract 1387).
   Google Scholar
• Witzig, T., Emmanouilides, C., Molina, A., Gordon, L., Gaston, I., Flinn, I.W., et al. (2003) "Yttrium-90 ibritumomab tiuxetan radioimmunotherapy (RIT) induces durable complete responses (CR/CRu) in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL)", Proc. Am. Soc. Clin. Oncol., 22, 579 (Abstract 2400).
   Google Scholar